Clinical Research & Data, Safety & Efficacy, AMI Cardiogenic Shock
Large Multicenter Study in Japan Finds High Survival Rates with Use of Impella® Heart Pump
A three-year, investigator-led, prospective study of Japanese patients who received an Impella® heart pump finds use of Impella is associated with a 77% survival rate at 30 days in AMI cardiogenic shock patients. The historic survival rate for cardiogenic shock is approximately 50%.
The interim analysis examined 819 patients treated with Impella for a variety of conditions, including cardiogenic shock and myocarditis, at 109 hospitals in Japan. Overall, investigators conclude the favorable 30-day survival data indicates Impella is a beneficial therapy.
A slide of improved survival with best practices is available for download here.